Equasens : RNPG virtually stable in 2023
The healthcare IT group posted annual sales of €219.7 million, up 2.6% despite an unfavorable base effect linked to the Ségur acquisition and a difficult economic climate, particularly in the pharmaceuticals market.
Equasens will propose a gross dividend of €1.25 per share (+9.2%) at the AGM on June 27. After a period of investment in 2024, it forecasts a return to double-digit sales growth from 2025 onwards.
In addition, at the proposal of CEO Denis Supplisson, the Board of Directors has approved the appointment of Damien Valicon, currently head of the Pharmagest division, to the position of non-executive Managing Director.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction